Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04785209
Other study ID # Prediction of No reflow
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date May 1, 2024

Study information

Verified date May 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores


Recruitment information / eligibility

Status Completed
Enrollment 640
Est. completion date May 1, 2024
Est. primary completion date February 28, 2021
Accepts healthy volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - patients presenting with acute STEMI, within 24 hours of symptoms, fulfilling criteria for PPCI protocol in our facility Exclusion Criteria: - patients presenting more than 24 hours of symptoms onset - patients not eligible for PPCI program in our facility

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mean platelet volume, lymphocyte number, STEMI clinical risk scores
Lab parameters

Locations

Country Name City State
Egypt Assiut university hospital Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participents with No reflow after PPCI and in hospital mortality No reflow: suboptimal myocardial reperfusion through a part of coronary circulation without angiographic evidence of mechanical vessel obstruction.
In hospital mortality
Within 48 hours from admission
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03264859 - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction N/A
Not yet recruiting NCT06342141 - Empagliflozin for No-reflow Phenomenon in PCI for STEMI Phase 2
Not yet recruiting NCT04835974 - the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT05360602 - Alpha Lipoic Acid Effect on No-Reflow Phenomenon N/A
Completed NCT02054000 - Intracoronary Tirofiban on No-Reflow Phenomena Phase 4
Not yet recruiting NCT05393557 - Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction N/A
Completed NCT04699110 - Adrenaline for the Treatment of No-Reflow in Normotensive Patients Phase 4
Completed NCT04573751 - The EPIVER Randomized Controlled Trial N/A
Not yet recruiting NCT02233790 - Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Phase 4
Recruiting NCT05427786 - A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease Phase 4
Completed NCT05355532 - Genetic Determinants of the Coronary Microvascular Obstruction in PCI